After a years-long legal battle, a judge has thrown out an unfair dismissal suit by a former TechnologyOne executive, finding he was lawfully terminated for failing to adapt to the company’s management structure.
A WiseTech investigation into billionaire chair Richard White has found no evidence that he misused company funds in his personal relationships with two women, including to pay for an employee’s plastic surgery.
Ashurst has nabbed a partner from Norton Rose Fulbright to join its global projects and energy transition team.
German drug maker Merck KGaA is fighting US drug company Merck Sharp & Dohme over the alleged use of the ‘Merck’ mark in Australia, five years after their intellectual property spat was settled.
A judge has expressed concerns about a funder’s novel application for its costs in a partially settled shareholder class action over the collapse of mining company Cudeco, saying everyone was getting a payday except group members.
A bid by the Victorian Liberal Party to summarily toss a challenge to a $1.5 million advance made to former leader John Pesutto for defence costs in a defamation suit has failed, with a court finding there is a case to be tried about the validity of the loan.
A group of insurers can’t join Northwest Rail Link joint venture partners MTR and UGL to a suit by CPB Contractors and John Holland over a $100 million policy, with a judge saying the joint venture’s interests in the case are commercial rather than legal.
The liquidators of Falcon Capital, which is suspected of having misused $450 million in investor funds, have sued a Melbourne property developer, claiming he knowingly assisted Falcon to loan millions in trust money in a “dishonest and fraudulent design”.
A judge has recused herself from a case by liquidators for real estate investment firm Global Capital Property Fund against Point Bay Developments, after hearing the corporate regulator’s application to wind up the fund.
Otsuka Pharmaceuticals has asked the High Court to overturn a decision revoking its Abilify patent extension, saying the ruling, which limited the extension-of term scheme to active substances only, will “lead to a groundswell of court proceedings”.